NCT07007208 · Phase 2 · NOT YET RECRUITING

Biomarkers of the Locus Coeruleus Nucleus: Links With Early Tau Pathology, Cognition and Alzheimer's Disease Risk

This trial is studying a brain region called the locus coeruleus, which may show early signs of tau protein buildup before other areas affected in Alzheimer's. Researchers will use PET scans, MRI, eye-tracking, and cognitive tests to see whether changes in this region predict Alzheimer's risk and memory problems. It is a Phase 2 observational study — researchers are measuring and learning, not testing a treatment.

You may qualify if

  • Participant in the INSPIRE-T cohort
  • Normal cognitive assessment
  • MMSE score ≥ 27 out of 30 (Mini-Mental State Examination)
  • Normal visual abilities (in corrected or uncorrected vision)
  • Normal motor skills

You're excluded if

  • Subjects with a contraindication to MRI exam
  • Subjects with a known allergic reaction to the PET radiopharmaceutical ([18F] Flortaucipir) or any of its excipients
  • Subjects with an ophthalmological pathology making oculometric measurements difficult
  • Subjects with neurological or psychiatric pathologies

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-12-16

View full record on ClinicalTrials.gov

All APOE4 clinical trials